Zura Bio Target of Unusually Large Options Trading (NASDAQ:ZURA)

Zura Bio Limited (NASDAQ:ZURA) was the recipient of unusually large options trading activity on Wednesday. Stock traders bought 2,384 call options on the company. This is an increase of 728% compared to the typical volume of 288 call options.

Insider Activity at Zura Bio

In related news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the firm’s stock in a transaction on Thursday, February 26th. The shares were purchased at an average cost of $6.25 per share, for a total transaction of $12,500,000.00. Following the completion of the acquisition, the insider directly owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. This trade represents a 43.93% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 22.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zura Bio

Several hedge funds have recently bought and sold shares of ZURA. Bank of America Corp DE raised its position in shares of Zura Bio by 3,007.7% in the 1st quarter. Bank of America Corp DE now owns 136,523 shares of the company’s stock valued at $812,000 after buying an additional 132,130 shares in the last quarter. Stempoint Capital LP acquired a new stake in shares of Zura Bio during the 1st quarter worth approximately $4,483,000. ADAR1 Capital Management LLC increased its stake in Zura Bio by 12.2% in the first quarter. ADAR1 Capital Management LLC now owns 630,403 shares of the company’s stock valued at $3,751,000 after acquiring an additional 68,338 shares during the last quarter. EcoR1 Capital LLC bought a new stake in Zura Bio during the first quarter worth $7,019,000. Finally, Commodore Capital LP bought a new stake in Zura Bio during the first quarter worth $19,338,000. 61.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Oppenheimer lowered their price target on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a report on Friday, March 20th. Chardan Capital lifted their price target on Zura Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, March 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Wednesday, April 8th. Finally, Wedbush began coverage on Zura Bio in a research report on Monday, February 9th. They set an “outperform” rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $10.75.

Zura Bio Trading Up 3.5%

NASDAQ ZURA traded up $0.14 during midday trading on Wednesday, hitting $4.13. The company had a trading volume of 72,823 shares, compared to its average volume of 656,238. The company has a market capitalization of $391.86 million, a PE ratio of -3.79 and a beta of 0.09. The firm has a 50-day moving average price of $5.58 and a 200-day moving average price of $5.22. Zura Bio has a twelve month low of $0.98 and a twelve month high of $7.44.

Zura Bio (NASDAQ:ZURA) last released its earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.05). On average, equities analysts anticipate that Zura Bio will post -0.73 EPS for the current year.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.